TY - JOUR AU - Kronenberger, Katrin PY - 2023/02/01 Y2 - 2024/03/29 TI - In dogs diagnosed with osteoarthritis, how safe and effective is long-term treatment with bedinvetmab in providing analgesia? JF - Veterinary Evidence JA - VE VL - 8 IS - 1 SE - Knowledge Summaries DO - 10.18849/ve.v8i1.598 UR - https://veterinaryevidence.org/index.php/ve/article/view/598 SP - AB - <p><strong>There is an erratum to this paper published in <em>Veterinary Evidence</em> Vol 8, Issue 3 (2023): <a href="https://doi.org/10.18849/ve.v8i3.668" target="_blank" rel="noopener">https://doi.org/10.18849/ve.v8i3.668</a></strong></p><p><strong>PICO question</strong></p><p>In dogs diagnosed with osteoarthritis (OA), how safe is treatment with bedinvetmab, when compared to a placebo and how effective in long-term reduction of the severity of the clinical signs associated with OA-related pain?</p><p> </p><p><strong>Clinical bottom line</strong></p><p><strong>Category of research</strong></p><p>Treatment.</p><p><strong>Number and type of study designs reviewed</strong></p><p>Two papers were critically reviewed. One was a randomised, blinded, multi-arm laboratory safety study; the other a multi-center field trial consisting of a block-randomised, double blind, placebo-controlled phase, followed by a non-comparative, open-label case series study.</p><p><strong>Strength of evidence</strong></p><p>Weak.</p><p><strong>Outcomes reported</strong></p><p>One study rated the reduction of the severity of clinical signs associated with OA pain using owner Canine Brief Pain Inventory (CBPI) ratings and non-validated veterinary clinical assessments (VCAs). Safety was addressed by evaluating adverse health effects (AHEs), concentration of antidrug antibodies (ADAs), and clinical pathology. Significant improvements in pain scores and VCAs were reported in this treatment study. The second safety-only study used clinical observation to evaluate AHEs. Both studies reported AHEs.</p><p><strong>Conclusion</strong></p><p>A single study suggests that treatment with bedinvetmab is effective. Two studies support the drug having few AHEs. Both studies have significant design limitations preventing the evaluation of bedinvetmab effectiveness. There is weak / inconclusive evidence for long-term efficacy and short-term safety of OA treatment with bedinvetmab. The decision to use bedinvetmab remains dependent on the judgement and experience of the clinician.</p><h3><a href="https://learn.rcvsknowledge.org/mod/book/view.php?id=50" target="_blank" rel="noopener">How to apply this evidence in practice</a></h3><p>The application of evidence into practice should take into account multiple factors, not limited to: individual clinical expertise, patient’s circumstances and owners’ values, country, location or clinic where you work, the individual case in front of you, the availability of therapies and resources.</p><p>Knowledge Summaries are a resource to help reinforce or inform decision making. They do not override the responsibility or judgement of the practitioner to do what is best for the animal in their care.</p> ER -